Evaluation of the current disease severity scores in paediatric FMF: is it necessary to develop a new one?

OBJECTIVES Modified adult disease severity scoring systems are being used for childhood FMF. We aim to test the clinical consistency of two common severity scoring systems and to evaluate the correlation of scores with the type of FMF mutations in paediatric FMF patients since certain mutations are prone to severe disease. METHODS Two hundred and fifty-eight children with FMF were cross-sectionally studied. Assessment of the disease severity was performed by using the modified scoring systems of Mor et al. and Pras et al. Genetic analysis was performed using PCR and restriction endonuclease digestion methods for the presence of 15 FMF gene mutations. FMF mutations were grouped into three based on well-known genotypic-phenotypic associations. Correlation between the mutation groups and the severity scoring systems was assessed. The consistency of the severity scoring systems was evaluated. RESULTS The results of two scoring systems were not statistically consistent with each other (κ = 0.171). This inconsistency persisted even in a more homogeneous subgroup of patients with only homozygote mutations of M694V, M680I and M694I (κ = 0.125). There was no correlation between the mutation groups and either of the scoring systems (P = 0.002, r = 0,196 for scoring systems of Mor et al.; P = 0.009, r = 0.162 for Pras et al.). CONCLUSIONS The inconsistency of the two scoring systems and lack of correlation between the scoring systems and mutation groups raises concerns about the reliability of these scoring systems in children. There is a need to develop a scoring system in children based on a prospective registry.

[1]  F. Retornaz,et al.  Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. , 2011, Seminars in arthritis and rheumatism.

[2]  S. Ozen,et al.  The Eurofever Project: towards better care for autoinflammatory diseases , 2011, European Journal of Pediatrics.

[3]  J. Pouchot,et al.  Extended Report , 2022 .

[4]  C. Dinarello,et al.  IL‐1: Discoveries, controversies and future directions , 2010, European journal of immunology.

[5]  E. Hasanoǧlu,et al.  Unresponsiveness to Colchicine Therapy in Patients with Familial Mediterranean Fever Homozygous for the M694V Mutation , 2010, The Journal of Rheumatology.

[6]  C. Dinarello Interleukin-1beta and the autoinflammatory diseases. , 2009, The New England journal of medicine.

[7]  A. Bakkaloğlu,et al.  Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease , 2008, Annals of the rheumatic diseases.

[8]  I. Dursun,et al.  Genotype–phenotype correlation in children with familial Mediterranean fever in a Turkish population , 2008, Pediatrics international : official journal of the Japan Pediatric Society.

[9]  D. Haffner,et al.  Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement , 2007, Pediatrics.

[10]  A. Chetrit,et al.  Evaluation of disease severity in familial Mediterranean fever. , 2005, Seminars in arthritis and rheumatism.

[11]  H. El-Shanti,et al.  Genotype/phenotype correlations in Arab patients with familial Mediterranean fever. , 2002, Seminars in arthritis and rheumatism.

[12]  Isabelle Touitou,et al.  The spectrum of Familial Mediterranean Fever (FMF) mutations , 2001, European Journal of Human Genetics.

[13]  E. Chouery,et al.  Familial Mediterranean fever in Lebanon: mutation spectrum, evidence for cases in Maronites, Greek orthodoxes, Greek catholics, Syriacs and Chiites and for an association between amyloidosis and M694V and M694I mutations , 2001, European Journal of Human Genetics.

[14]  I. Touitou,et al.  Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. , 2000, Rheumatology.

[15]  M. Pras,et al.  Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. , 2000, The Journal of rheumatology.

[16]  M. Tekin,et al.  Genotype-phenotype correlation in a large group of Turkish patients with familial mediterranean fever: evidence for mutation-independent amyloidosis. , 2000, Rheumatology.

[17]  M. Berant,et al.  Familial Mediterranean Fever: Clinical and Genetic Characterization in a Mixed Pediatric Population of Jewish and Arab Patients , 1999, Pediatrics.

[18]  T. Shohat,et al.  Phenotype–genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis , 1999, European Journal of Human Genetics.

[19]  M. Ehrenfeld,et al.  Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. , 1999, American journal of medical genetics.

[20]  A. Bernot,et al.  Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever (FMF) , 1998, European Journal of Human Genetics.

[21]  D. Zemer,et al.  Criteria for the diagnosis of familial Mediterranean fever. , 1997, Arthritis and rheumatism.

[22]  R. Petty,et al.  Textbook of pediatric rheumatology , 1982 .

[23]  J. M. Marco Franco,et al.  [Familial Mediterranean fever and amyloidosis]. , 1982, Revista clinica espanola.

[24]  Michael J. Campbell,et al.  Statistics at Square One , 1976, British medical journal.